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Abstract
Background: Human papilloma virus (HPV)-16 is the most prevalent high-risk mucosal genotype. Virus-like-particle
(VLP)-based immunogens developed recently have proven to be successful as prophylactic HPV vaccines, but are
still too expensive for developing countries. Although vaccinia viruses expressing the HPV-16 L1 protein (HPV-L1)
have been studied, fowlpox-based recombinants represent efficient and safer vectors for immunocompromised
hosts due to their ability to elicit a complete immune response and their natural host-range restriction to avian
species.
Methods: A new fowlpox virus recombinant encoding HPV-L1 (FPL1) was engineered and evaluated for the correct
expression of HPV-L1 in vitro, using RT-PCR, immunoprecipitation, Western blotting, electron microscopy,
immunofluorescence, and real-time PCR assays.
Results: The FPL1 recombinant correctly expresses HPV-L1 in mammalian cells, which are non-permissive for the
replication of this vector.
Conclusion: This FPL1 recombinant represents an appropriate immunogen for expression of HPV-L1 in human cells.
The final aim is to develop a safe, immunogenic, and less expensive prophylactic vaccine against HPV.
Background
Cervical cancer caused by human papilloma virus (HPV)
is the second leading cause of malignancies in women
worldwide, and the first in developing countries. Persis-
tent infection with one of the approximately fifteen high-
risk oncogenic HPV types can cause the onset of cervical
intraepithelial neoplasia and progression to invasive cer-
vical cancer [1]. Approximately 500,000 cases are diag-
nosed every year, resulting in 274,000 deaths [2,3].
The absence of specific antiviral drugs has stimulated
the search for prophylactic vaccines against HPV-16 and
HPV-18, which are the HPV genotypes that are most
commonly associated with the disease. In particular,
HPV-16 is by far the most prevalent high-risk mucosal
genotype, and, as it is present in around 50% of all
cervical cancers [1,4,5], it has been the focus of many
recent vaccine developments.
Although therapeutic vaccines are of high priority for
the control of progression to neoplasia in subjects who
are already infected, prophylactic vaccines are important
to limit the diffusion of infection. They are therefore the
best choice for intervention against HPVs, as they can
neutralise the incoming virus and prevent disease
progression.
The preparation of a new vaccine has been hampered
for a long time because of the restricted host range of
the virus and its selective tropism for differentiated
squamous epithelium, which makes its growth in cell
culture difficult. Expression of the L1 major capsid pro-
tein of HPV-16 (HPV-L1) in eucaryotic cells results in
the formation of empty virus capsids (virus-like parti-
cles; VLPs) [6] which are very similar to native virions,
show icosahedral symmetry, and can enter cells like
infectious virions. In particular, VLPs have proven to be
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any medium, provided the original work is properly cited.successful as prophylactic bivalent [7] and quadrivalent
[8] HPV vaccines in women, by eliciting virus-neutralis-
ing antibodies in large randomized controlled clinical
trials [9-11]. They have also shown higher immunogeni-
city than capsomers, although similar titres of neutralis-
ing antibodies can be induced using strong immune
adjuvants [12]. VLPs enter the MHC-II processing path-
way and they can induce a CD4-restricted T-cell
response, which is important for both robust antibody
and memory responses, as has been summarized in dif-
ferent reviews [13-15]. Different studies also suggest
that VLPs can also deliver foreign protein to the MHC-I
pathway to elicit cytotoxic T-cell responses [16-18].
However, VLPs are still too expensive for less-developed
countries, they are not thermostable, and they need to
be delivered by injection.
Immunisation with vaccinia virus recombinants
expressing HPV genes or other viral antigens has been
demonstrated to be a good candidate for stimulation of
the immune system [19]. However, their use has raised
safety concerns due to severe collateral effects in immu-
nocompromised individuals [20]. VLPs have also been
produced in plant in various studies [21,22], and also as
a chimeric L1 fused with cytotoxic E6 epitopes [23].
The avipox viruses, and the fowlpox virus (FP) in particu-
lar, represent alternative vectors due to their natural host-
range restriction to avian species [24,25], to their correct
expression of transgenes in mammalian cells, and to their
elicitation of a long-lasting immune response in the vacci-
nated hosts [26,27]. Compared to VLP-based HPV vaccines
that are produced by yeast or baculovirus, and that mainly
induce humoral responses, FP-based recombinants elicit a
complete and more effective immunity. Moreover, as these
FP-based recombinants do not immunologically cross-react
with vaccinia viruses, they can be administered to pre-
viously vaccinia-virus-experienced individuals, thus circum-
venting neutralisation by vector-generated immunity [28].
These viruses have thus acquired an important role in the
development of novel vaccines against human diseases, as
they may represent safer vectors than wild-type or attenu-
ated vaccinia viruses [24,29].
In the present study, a new FP recombinant encoding
HPV-L1 (FPL1) was engineered and evaluated for its cor-
rect expression in vitro, with the final aim of developing
a prophylactic vaccine. This recombinant should express
foreign genes intracellularly and allow cross-presentation
of the antigen in association with both MHC class I and
II complexes, thus eliciting a complete humoral and cel-
lular protective immunity.
Methods
Cells
CaSki cells carrying multiple copies of integrated HPV-
16 DNA, green monkey kidney (Vero) cells, and MRC-5
human lung fibroblasts were grown in Dulbecco’s modi-
fied Eagle’s medium (DMEM) supplemented with 10%
heat-inactivated calf serum (Gibco/Invitrogen, Carlsbad,
CA, USA), 100 U/ml penicillin and 100 μg/ml strepto-
mycin (P/S). Specific-pathogen-free primary chick
embryo fibroblasts (CEFs) were grown in DMEM with
5% heat-inactivated calf serum, 5% tryptose phosphate
broth (TPB; Difco Laboratories, Detroit, MI, USA), and
P/S.
Production of HPV-16 L1
The pQE30 expression plasmid (Qiagen, Valencia, CA,
USA) engineered to contain the L1 gene of HPV-16 [30]
(pQE30-L1-NLS-His) was kindly supplied by C. Giorgi
(Istituto Superiore di Sanità, Rome, Italy). After its clon-
ing into JM109 bacterial cells, this engineered plasmid
was used for the production of the RGS/L1/His-tagged
protein, according to the manufacturer instructions
(Qiagen), with minor modifications. Briefly, JM109/
pQE30-L1-NLS-His bacterial cells were lysed in phos-
phate lysis buffer (300 mM NaCl, 1% Triton X-100, pH
8, prepared in buffer A: 10 mM Tris, 100 mM
Na2HPO4, 6 M guanidine-HCl, pH 8). After clarification
for 30 min at 17,000 × g at 4°C, the supernatant con-
taining the HPV-L1 preparation was supplemented with
1% Triton X-100/20 mM imidazole, pH 8, in buffer A.
This was then incubated with Ni-NTA agarose resin
(Qiagen) for 30 min at room temperature. After washing
once with 1% Triton X-100 in buffer A, twice with buf-
fer A, and multiple times with buffer C (100 mM
Na2HPO4, 10 mM Tris, 8 M Urea, pH 6.3) up to a final
optical density of 0.013, the protein was eluted into dif-
ferent fractions with 1 M imidazole, pH 8. After their
analysis by 15% PAGE, the fractions enriched in the
recombinant HPV-L1 were pooled. The HPV-L1 was
dialysed overnight at 4°C using a slide-A-lyser cassette
(10 kDa MW cut-off, Pierce, Rockford, IL, USA), and
soaked in dialysis buffer (25 mM Tris-HCl, 100 mM
NaCl). The protein was quantified, stored at -80°C and
used as a control in the Western blotting.
Construction of the recombination plasmid
T h eL 1g e n eo fH P V - 1 6w a sa m p l i f i e df r o mt h ep U F 3 /
L1 plasmid that contained the humanised HPV-L1 gene
sequence (1,518 bp; accession number: AJ313179) [31]
kindly supplied by M. Mueller (German Cancer
Research Center, Heidelberg, Germany). This was
inserted into the multicloning site (MCS) downstream
of the early/late VVH6 promoter [32,33] of the pFP-
MCS-GFP plasmid. The enhanced GFP (green fluores-
cent protein) gene derived from pEGFP-N1 (BD Bios-
ciences Clontech Laboratories, Inc., Mountain View,
CA, USA) is therefore located downstream of the L1
gene, but in the reverse orientation and under the
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Siccardi, HSR, Milan, Italy). The L1 and GFP genes are
both inside the two arms of the 3-b-hydroxysteroid
dehydrogenase 5-delta 4 isomerase gene (DH) fowlpox
gene, used for site-specific in-vitro recombination [35].
The DNA sequence encoding the complete L1 region of
HPV-16 was amplified using the V178 (5’-GCC-GCG-
CCC-GGG-AAG-CTT-ATG-AGC-CTG-TGG-CTG-
CCC-AGC-GAG-3’)a n dV 1 7 9( 5 ’-GCC-GCG-GTC-
GAC-AAG-CTT-TCA-CAG-CTT-CCT-CTT-CTT-CC-
3’) primers. The amplification was carried out starting
from 250 ng DNA in a final volume of 50 μl, in a mix-
ture containing 1 μM of each primer, 200 μM of each
dNTP, 3 μMM g C l 2,2 . 0m MM g S O 4, and 0.025 U/μl
Pwo DNA polymerase (Boehringer Mannheim, Indiana-
polis, IN, USA). The PCR conditions were: 95°C for 45
s, followed by 30 cycles at 95°C for 30 s, 70°C for 30 s,
72°C for 80 s, and 72°C for 7 min (PTC-200 thermocy-
cler; MJ Research, Waltham, MA, USA). The HPV-L1
gene was first cloned into the pCR-BluntII-TOPO plas-
mid (Invitrogen, Carlsbad, CA, USA), which allows the
insertion of blunt-ended sequences. The pCR-BluntII-
TOPO/L1 was then cut out with HindIII (Fermentas,
M-Medical, Milan, Italy) and ligated into the pFP
recombinant vector, which had been previously line-
arised with HindIII for 1 h at 37°C. Ligation was carried
out overnight at 16°C in 10 μl, using 1 U T4 DNA ligase
(USB, Amersham-Pharmacia Biotech AB, Uppsala, Swe-
den) and 100 ng of the insert at an insert:vector molar
ratio of 3:1. After transformation of supercompetent
ECL bacterial cells, the colonies were screened by ampli-
fying the HPV-L1 gene, and further analysed by diges-
tion with the NruI/KpnI and HindIII/EcoRI restriction
enzymes, to verify the correct orientation of the insert.
The cloned recombinant plasmid was purified (Qiagen,
Hilden, Germany) and sequenced (Genenco, MMedical,
Milan, Italy) to exclude any possible mutation arising
from PCR amplification. This cloned recombinant plas-
mid is henceforth referred to as pFPL1 (9,726 bp).
In-vitro recombination to generate the FPL1 recombinant
The FPL1 recombinant was obtained by in-vitro recom-
bination in specific-pathogen-free primary CEFs, as
d e s c r i b e dp r e v i o u s l y[ 3 5 , 3 6 ] ,u s i n gt h ew i l d - t y p eF P
virus (FPwt) and pFPL1.B r i e f l y ,t h eC E F sw e r ei n f e c t e d
with 0.5 PFU/cell FPwt in DMEM containing 2% foetal
calf serum, and, after a 4-h incubation at 37°C, they
were transfected by calcium phosphate precipitation
using 125 μgp F P L1 DNA in 1 ml of a mixture contain-
ing 125 μMC a C l 2 in 40 mM HEBS, pH 7, 300 mM
NaCl, 1.4 mM Na2HPO4, 10 mM KCl, and 12 mM dex-
trose. Two days after the infection, the FP virus was
released from the cells by three freeze-thaw cycles and
used for further infection and selection of the
recombinants. Recombinant plaques were identified by
autoradiography after hybridisation with a [
32P]-labelled
HPV-L1 probe, and then subjected to multiple cycles of
plaque purification. One clone was selected for correct
and highest expression of the HPV-L1 gene by Western
blotting. The FPL1 recombinant was amplified in CEFs
and purified on a sucrose gradient, as described pre-
viously [33].
mRNA transcript expression in replication-restrictive Vero
cells
The expression of the HPV-L1 gene was first deter-
mined by RT-PCR, after infecting Vero cells with 5 PFU
of FPL1 recombinant. The experiments were performed
in duplicate. RNA was extracted 1 day post-infection (p.
i.) and every 3 days for 21 days, using Trizol LS (Gibco)
to determine the level of HPV-L1 transcripts in non-
permissive mammalian cells. The mRNAs from all of
the samples were treated with 10 U RNase-free DNase I
(Roche Diagnostics, Indianapolis, IN, USA) for 4 h at
37°C, to eliminate any cellular or viral DNA, then preci-
pitated with 100% ethanol in the presence of 100 mM
Na acetate. After washing in 75% ethanol and resuspen-
sion in diethylpyrocarbonate-treated water, RT-PCR was
carried out using the Access RT-PCR System kit (Pro-
m e g a ,M a d i s o n ,W I ,U S A ) .B r i e f l y ,5 0n gR N Af r o m
each sample was used in a final volume of 20 μl, in the
presence of 1 mM of each primer, 200 mM of each
dNTP, 0.1 U/ml Tfl DNA polymerase, 0.1 U/ml AMV
reverse transcriptase (AMV-RT), and 2.0 mM MgSO4.
Control samples without AMV-RT were also prepared.
The presence of the HPV-L1 transcript was verified
using the V191 (5’-CGA-CAC-CAG-CTT-CTA-CAA-C-
3’)a n dV 1 9 0( 5 ’-TGT-TGA-ACA-GGT-GCC-TC-3’)
primers. Human b-actin was also amplified as an inter-
nal control, using the V84 (5’-CTG-ACT-ACC-TCA-
TGA-AGA-TCC-T-3’)a n dV 8 5( 5 ’-GCT-GAT-CCA-
CAT-CTG-CTG-GAA-3’)p r i m e r s ,a n dab a n do f5 1 8
bp was obtained. Mock-infected Vero cells were used as
an e g a t i v ec o n t r o l .T h er e v e r s et r a n s c r i p t a s er e a c t i o n
was carried out at 48°C for 45 min, followed by 2 min
at 94°C. PCR amplification was performed for 35 cycles
a t9 4 ° Cf o r3 0s ,6 0 ° Cf o r3 0s ,a n d6 8 ° Cf o r1m i n ,f o l -
lowed by a final incubation at 68°C for 7 min. For
human b-actin, the RNA (50 ng) amplification was car-
ried out as described above, but with 1 mM MgSO4.
The thermal profile was at 48°C for 45 min followed by
94°C for 2 min and 40 cycles at 94°C for 30 s, 58°C for
30 s, 68°C for 1 min, and with a final extension of 68°C
for 7 min. The PCR products were run on 1% agarose
gels and the gel images were acquired using a Speedlight
Platinum apparatus (Lightools Research, Encinitas, CA,
USA). The RT-PCR products were quantified using the
ImageJ software [37].
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The cells were infected with 5 PFU/ml in DME methio-
nine-, cystine-, and L-glutamine-free medium (DMEM
met
-, cys
-, glut
-, MP Biomedicals Inc, DBA, Milan, Italy).
After 2 h, 20 μCi/ml [
35S]-methionine and [
35S]-cysteine
were added, using the same medium supplemented with
2% dialysed foetal bovine serum (Gibco). Sixteen hours
p.i., the cells in 2 ml of medium were harvested by
resuspending them in 1 ml lysis buffer (150 mM NaCl,
1 mM EDTA, 10 mM Tris-HCl, pH 7.4, 0.2 mg/ml
PMSF, 1% NP40, 0.01% sodium azide) and 0.6 TIU
aprotinin (Sigma, St Louis, MO, USA) per Petri dish,
with scraping into microcentrifuge tubes (Eppendorf,
Milan, Italy). The lysate was clarified by centrifugation
at 9,000 × g for 20 min at 4°C. Immunoprecipitation
was performed either with 2 μl anti-HPV-L1 pread-
sorbed polyclonal mouse serum (C. Giorgi) or with a
monoclonal antibody (CamVir-1; BD Biosciences, San
Diego, CA, USA). Proteins were resolved using 12.5%
SDS-PAGE, and fluorographed.
Western blotting
To determine whether HPV-L1 was expressed correctly
by the FPL1 recombinant, Vero cells were infected with
5P F U / c e l lF P L1 recombinant and examined by Western
blotting. The pelleted cells were lysed in sample buffer
(50 mM Tris, pH 6.8, 10% SDS, 1.5% dithiothreitol,
0.05% bromophenol blue), boiled for 5 min, and loaded
onto polyacrylamide gels. After running through a 4%
stacking gel for 1 h at 20 mA and through a 15% run-
ning gel for 1.5 h at 40 mA, the proteins were trans-
ferred onto 0.2 μm nitrocellulose membranes (Bio-Rad
Laboratories, Milan, Italy) for 1 h at 100 V in cold
transfer buffer (150 mM glycine, 20 mM Tris, 20%
methanol) using a transblot apparatus (Bio-Rad). Soon
after the protein transfer to the nitrocellulose, the posi-
tions of protein markers (Precision Plus Protein™ All
blue standards, Bio-Rad) (5 μl/gel) were marked on the
nitrocellulose. The nitrocellulose membranes were incu-
bated for 30 min in 0.5% glutaraldehyde (Polysciences,
Inc., Warrington, PA, USA), washed in H2O, and incu-
bated for 1 h with 5% skimmed milk (Merck, West
Point, PA, USA) in Ca
2+-free and Mg
2+-free phosphate-
buffered saline (PBS
-). After three rinses in wash buffer
(20% Tween in PBS
-), the nitrocellulose membrane was
incubated overnight at 4°C with a 1:5,000 dilution of the
specific anti-HPV-L1 CamVir-1 antibody (BD Bios-
ciences). The washing was followed by a 1-h incubation
with a goat anti-mouse horseradish peroxidase antibody
(1:10,000 dilution; Dako Cytomation), and 2-h washes,
before the HPV-L1 was revealed using the ECL system
(GE Healthcare, Buckinghamshire, UK). The densito-
metric analysis of the Western blotting bands of the L1
protein was performed using the ImageJ software [37].
Immunofluorescence
The expression of HPV-L1 was also examined by immu-
nofluorescence. Vero cells were seeded at a density of 5
×10
5/35-mm
2 dish on sterile glass coverslips, before
infection with 5 PFU/cell FPL1 recombinant at 37°C for
1 h. After a 6-h incubation at 37°C in DMEM supple-
mented with 2% foetal calf serum and P/S, the cells
were washed twice with PBS
-, fixed with 2% paraformal-
dehyde (Polysciences) in PBS
- for 10 min at room tem-
perature, followed by 100% cold acetone for 5 min at 4°
C. The samples were incubated with either monoclonal
CamVir-1 (BD Biosciences, 1:100) or mouse (C. Giorgi,
1:50) or rabbit (R20, from our laboratory, 1:500) polyclo-
nal anti-HPV-L1 antibodies, followed by a 1:100 FITC
antiserum (Cappel, MP Biomedicals, Inc., Aurora, OH,
USA). The R20 antibodies were obtained by multiple
inoculations of one rabbit with the FPL1 recombinant.
Before use, serum from R20 was immmunoadsorbed
overnight with FPwt-infected Vero cells to remove anti-
bodies raised against the vector. FPwt-infected Vero
cells were used as a negative control, while CaSki and
HeLa cells were used as positive controls. Samples were
viewed under a Zeiss Axioskop fluorescence microscope.
Transmission electron microscopy
Confluent Vero, MRC-5, and CEFs cells were infected
with the FPL1 recombinant and FPwt at 5 PFU/cell for 1
h at 37°C. On days 1 and 3 p.i., the cells were harvested
for transmission electron microscopy (TEM). After cen-
trifugation at 1,000 × g for 10 min at room temperature,
the cells were fixed in 2.5% glutaraldehyde (Poly-
sciences) in 0.1 M Na cacodylate buffer, pH 7.4, for 1 h
at 4°C. They were then rinsed twice, and post-fixed in
cacodylate-buffered 1% OsO4 at 4°C for 1 h. The speci-
mens were dehydrated through a series of graded etha-
nol solutions and propylene oxide, and embedded in
Poly/Bed 812 resin mixture. Ultrathin sections were
obtained using a Sorvall MT2B ultramicrotome
equipped with a diamond knife, and they were stained
with water-saturated uranyl acetate and 0.4% lead citrate
in 0.1 M NaOH. VLPs from the commercial HPV Gar-
dasil
® vaccine were negative-stained with water-satu-
rated uranyl-acetate and used as a control. The
specimens were viewed with a Philips CM10 electron
microscope.
Real-time PCR
RNA was extracted from Vero cells infected with 2
PFU/cell FPL1 recombinant, and harvested on days 1, 2,
7, 10, 14, 18 and 22 p.i.. The cells were rinsed twice
with PBS
-, scraped from the Petri dishes with a rubber
policeman, and centrifuged at 1,500 × g for 5 min. After
lysis, the RNAs were extracted using the RNeasy mini
kit (Invitrogen, Carlsbad, CA, USA), according to the
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tions were performed in a final volume of 50 μl, using 3
μg RNA and the High Capacity cDNA Archive kit (PE
Applied Biosystems, Foster City, CA, USA). The reac-
tions were performed at 25°C for 10 min, followed by
48°C for 30 min, and 95°C for 5 min. The cDNA (5 μl)
was then added to each well of a MicroAmp Optical 96-
well reaction plate (Applera, PE Applied Biosystems) in
the presence of 2× Power SYBRA green master mix, and
forward V392 (5’-GGA-GTA-CGA-CCT-GCA-GTT-
CAT-CT-3’) and reverse V393 (5’-CTG-CGT-TCA-
TCG-TGT-GGA-TGT-3’) primers to identify the HPV-
L1 gene, in a final volume of 25 μl. The primers V385
(5’-AGC-AAA-GAC-CCC-AAC-GAG-AA-3’)a n dV 3 8 6
(5’-GGC-GGC-GGT-CAC-GAA-3’)w e r eu s e df o rt h e
GFP gene, V380 (5’-TGG-AGA-TGA-ACT-CGG-ACC-
TC-3’)a n dV 3 8 1( 5 ’-CGA-CCA-CCA-CCA-ACT-TCA-
A-3’) for the housekeeping RPS7 human gene. FPwt-
infected Vero cells and Vero cells transfected for 24 h
with the pUF3/HPV-L1 plasmid (kindly supplied by M.
Mueller, German Cancer Research Centre, Heidelberg,
Germany) or the pEGFP plasmid were used as negative
and positive controls, respectively. All of the reactions
were performed in an ABI PRISM 7700 apparatus (PE
Applied Biosystems). The PCR conditions were 50°C for
2 min, 95°C for 15 min, followed by 40 cycles at 95°C
for 15 s and 60°C for 1 min. A 20-min dissociation pro-
tocol was also applied. Two different analyses were per-
formed and the copy numbers of the HPV-L1 and GFP
transcripts were calculated using the comparative Ct
method (also known as the 2
-[delta] [delta]Ct method),
where [delta] Ct, sample =C t,L1 -C t, RPS7, [delta] Ct, sample
is the Ct value for any sample normalised to the RPS7
endogenous housekeeping transcripts and [delta] [delta]
Ct =[ d e l t a ] C t, sample - [delta]Ct, wt. In all of the samples,
the 2
-[delta] [delta]Ct refers to an N-fold increase of HPV-
L1/GFP copy number relative to the control.
Results
FPL1 recombinant expresses the mRNA up to day 21 p.i.
in non-permissive mammalian cells
The expression of the HPV-L1 transgene after infection by
the FPL1 recombinant was tested over time by RT-PCR.
The mRNA isolated from infected Vero cells showed that
the gene carried by the FPL1 recombinant amplified as a
band of 530 bp (Figure 1). In particular, HPV-L1 transgene
expression was detectable from 3 days p.i., and extended
up to day 21 p.i.. The expression levels were determined
by densitometric analysis, and they showed that a very
high level of expression was maintained up to day 9 p.i.,
which then constantly decreased. The similar levels of
amplification of b-actin RNA (518 bp) over time con-
firmed the reliability of these differences in HPV-L1
expression. Mock-infected cells were always negative, as
were cells infected with FPwt and those amplified in the
absence of AMV-RT (data not shown).
HPV-L1 is expressed in mammalian cells, although at low
levels
To determine whether HPV-L1 transcripts were fol-
lowed by the synthesis of the corresponding viral pro-
teins, immunoprecipitation was performed on Vero,
MRC-5, and CEFs cells (Figure 2A). HPV-L1 was
detected only in MRC-5 cells (Figure 2A, lane 6), using
either monoclonal or rabbit polyclonal antibodies. In
the FPL1-infected Vero cells, protein expression was
not detectable (Figure 2A, lane 3) as well as in CEFs
(data not shown), and in mock-infected (Figure 2A,
lanes 1 and 4) and FPwt-infected (Figure 2A, lanes 2
and 5) cells. These data prompted us to confirm these
results by Western blotting with the same cell lines
(Figure 2B). The results showed expression of HPV-L1
not only in MRC-5 cells (Figure 2B, lane 5) but also in
Vero cells infected by the FPL1 recombinant (Figure
2B, lanes 2, 55-58 kDa). The densitometric analysis of
the Western blotting bands of the L1 protein produced
by the FPL1 recombinant was compared to the band of
a known amount of purified L1 protein used as a stan-
dard; this showed that 10
7 Vero and MRC-5 cells pro-
duced 42 ng and 52 ng of protein, respectively. HPV-
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Figure 1 Expression of the HPV-L1 transcript over time by RT-
PCR. After infecting Vero cells with the FPL1 recombinant, in
duplicate, the expression of the transgene was evaluated every 3
days. The expression levels, as determined by densitometric analysis,
extended up to day 21 p.i. (530 bp). The data are expressed as
means (±standard deviation). Amplification of b-actin RNA (518 bp)
is also shown. Mock-infected cells were always negative, as were
cells infected with FPwt or amplified in the absence of AMV-RT
(data not shown).
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used as a molecular-weight marker (Figure 2B, lane 6)
and CaSki cells as a positive control (Figure 2B, lane
3). No specific bands were seen when Vero cells were
infected with FPwt (Figure 2B, lanes 1 and 4) or in
replication-permissive CEFs (data not shown). It is
worth noting that although different monoclonal and
polyclonal antibodies were used to determine the
expression of HPV-L1, only the monoclonal BD anti-
body showed specificity and high avidity in all of the
different tests.
Immunofluorescence results
To determine the localisation of HPV-L1, immunofluor-
escence (Figure 3) was performed on Vero, MRC-5, and
CEFs cells infected with the FPL1 recombinant. In all
these different cell types, which were either non-permis-
sive (Vero and MRC-5, Figure 3, 1b, 2b) or permissive
(CEFs, Figure 3b) for replication, immunofluorescence
was detected at the nuclear level using monoclonal or
polyclonal antibodies. No fluorescence was seen in the
respective different cell types infected with FPwt (Figure
3, 1a, 2a, 3a). As expected, CaSki and HeLa cells used as
positive controls showed clear nuclear immunofluores-
cence (data not shown).
Only limited amounts of VLPs are found in Vero and
MRC-5 cells
Structural capsid proteins can self-assemble into VLPs
spontaneously. Non-permissive Vero (Figure 4A) and
MRC-5 (Figure 4B) cells, as well as permissive CEFs
(not shown), were infected with the FPL1 recombinant,
and VLP formation was examined at the ultrastructural
level by electron microscopy. In both Vero and MRC-5
cells, FPL1 recombinant virions were seen attached to
the cell membrane (data not shown). Complete VLPs
(T7, 72 pentamers) were seen in Vero cells at different
times p.i., although in limited amounts and mainly
enclosed in pseudo-vacuoles (Figure 4A). These pseudo-
vacuoles seem to be the result of tangential sections of
invaginations of the cell membrane, as shown by the
unstructured background characteristics of the extracel-
lular environment. In MRC-5 cells, only unassembled
particles (T1, 12 pentamers) were seen in the nucleus
(Figure 4B), whereas they could not be detected in FPL1-
infected CEFs (data not shown).
4 5 6 
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mock FPwt FPL1 
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Figure 2 Transcript expression by immunoprecipitation (A) and Western blotting (B). HPV-L1 expression was tested in cells infected with 5
PFU/cell of the FPL1 recombinant virus. By immunoprecipitation, HPV-L1 was detected only in MRC-5 cells (A, lane 6), whereas by Western
blotting HPV-L1 expression was seen not only in MRC-5 cells (B, lane 5), but also in Vero cells (B, lane 2). Both immunoprecipitation and Western
blotting were performed using the CamVir-1 monoclonal antibody. HPV-L1 produced by an engineered bacterial vector was used as a molecular
weight marker (lane 6) and CaSki cells as a positive control (lane 3). No specific proteins were seen in mock-infected (A, lanes 1, 4) and FPwt-
infected (A, lanes 2, 5; B, lanes 1, 4) cells or in replication-permissive CEFs (data not shown). HPV-L1 (B, lane 6) and CaSki cells (A, lane 7; B, lane
3), used as positive controls, also showed a clear 55-kDa band.
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Page 6 of 11GFP is well expressed over time
To determine whether the limited amount of VLPs can
be ascribed to the interaction of the HPV-L1 and GFP
genes driven by the VVH6 and SP promoters, respec-
tively, a quantitative comparison between the HPV-L1
and GFP transcripts was performed over 3 weeks by
real-time PCR at different days p.i. (Figure 5). The GFP
mRNAs were expressed over time at a good level as
well as the HPV-L1 transcripts, reaching their maximum
expression level on day 7 p.i..
Discussion
HPV-16 infection is the major risk factor for the devel-
opment of cervical neoplasia and invasive cancer [38],
and its evidence as the primary aetiologic agent of cervi-
cal cancer has been shown across a wide variety of epi-
demiologic and experimental studies [39]. The
expression of the major L1 capsid protein of papilloma-
virus (HPV-L1) leads to self-assembly of VLPs, that dis-
play conformational epitopes recognised by neutralizing
monoclonal antibodies [40], as has been demonstrated
using baculovirus-transduced insect cells [41,42] or
yeast [43-45]. The preventive VLP-based vaccines, that
have been recently developed (Gardasil
®,M e r c k ;C e r -
varix
®, Glaxo SmithKline Biologicals) and approved for
immunisation programmes in several countries [46], are
effective in eliciting protective immunity through induc-
tion of a prominent humoral response [6,13,14,47].
However, their cost is unaffordable by the healthcare
systems of less-developed countries, where the incidence
of HPV-associated disease is extremely high, and the
vaccine is most needed, also because HIV-positive sub-
jects are unable to clear HPV infections. Also, as seen
for non-replicating vaccines, VLPs are endocytosed by
antigen-presenting cells, mainly presented to CD4
+ T-
lymphocytes in association with MHC class II mole-
cules, and require boost inoculations to maintain high
antibody levels and immune cell memory. Recombinant
live viral vaccines driving HPV transgene expression
represent an attractive alternative as they might induce
humoral and cellular immune responses and a long-last-
ing immunity without the need for numerous recalls.
In the present study, we have described the construc-
tion, transcription and protein expression of a new FP
recombinant containing the humanised L1 gene of HPV-
16, and we have demonstrated that: (1) HPV-L1 is cor-
rectly expressed in mammalian cells, as demonstrated by
RT-PCR, immunoprecipitation, Western blotting, and
real-time PCR; (2) in spite of the abortive replication of
the FP virus vector in mammalian cells, the transcription
of HPV-L1 is long lasting; (3) HPV-L1 is localised at the
nuclear level, as seen by immunofluorescence; (4) L1 self-
assembles both as T1 particles and as VLPs, and it can be
found both in non-human and human primate cells.
The long-lasting expression of the HPV-L1 transcripts
in mammalian cells confirms the possibility for a non-
Vero FPwt 
23/5/11 3.2  
1a 
mrc5 FPwt 
25/5/11 5.1  
CEF FPwt 
23/5/11 8.3  
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25/5/11 7.3  
CEF FPL1 
23/5/11 10.3  
2a 
3a 
2b 
3b 
Vero FPL1 
23/5/11 6.4  
1b 
Figure 3 Heterologous protein expression by immunofluorescence. In all the different, either non-permissive (Vero and MRC-5 cells, 1b, 2b)
or permissive (CEFs, 3b) cell types, immunofluorescence was detected at the nuclear level, using the CamVir-1 antibody. No fluorescence was
seen in the respective different cell types infected with FPwt (1a, 2a, 3a). As expected, the CaSki and HeLa cells used as positive controls showed
clear nuclear immunofluorescence (data not shown).
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Page 7 of 11replicating recombinant vector to induce a good
immune response [48]. As the HPV-L1 was found by all
of the assays in MRC-5 but not in CEFs cells, we have
hypothesised that HPV-L1 expression was mainly lim-
ited to human cells due to the humanised HPV-L1 gene
sequence that was used for the FPL1 recombinant
construction. However, detection of HPV-L1 also in
non-human primate Vero cells by Western blotting
instead suggests that although present, only the non-
native HPV-L1 structure can be detected in these cells.
The absence of any specific band in FPL1-infected CEFs
both by immunoprecipitation and Western blotting can
N
C B A
Figure 4 VLP production in Vero and MRC-5 cells. Cells infected with the FPL1 recombinant were fixed 3 days p.i., and VLP formation was
examined at ultrastructural level by electron microscopy. Complete VLPs (T7, 72 pentamers) were found in Vero cells mainly enclosed in pseudo-
vacuoles (A). Unassembled T1-particles (12 pentamers) were present in the nuclei of MRC-5 cells (B). No VLPs were detected in FPL1-infected
CEFs (data not shown). Negative-stained VLPs from the commercial HPV Gardasil
® vaccine (inset of panel A) were used as a control. An
enlargement of the nuclear T1 particles is shown in the inset of panel B. Bar in Panels A and B: 300 nm. Bar in the insets: 100 nm.
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Figure 5 Expression of HPV-L1 and GFP transcripts over time using real-time PCR in restrictive mammalian cells. After infecting Vero
cells with 2 PFU/cell of the FPL1 recombinant, quantitative expression of the HPV-L1 and GFP transgenes was evaluated every 3 days for 22
days. The maximum expression level for both HPV-L1 and GFP were reached on day 7 p.i., and GFP mRNAs were always highly expressed. The
copy number of HPV-L1/GFP mRNAs, normalised to the RPS7 endogenous housekeeping transcripts, refers to the N-fold increase vs control
mRNA at each time point. The data are expressed as means (±standard deviation) from two independent analyses.
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Page 8 of 11be ascribed to the prevalent expression of the early and
late genes of the vector and to its cytopathogenicity,
which might prevent expression of the heterologous
HPV-L1 transgene.
On the other hand, the HPV-L1 expression in CEFs
determined by immunofluorescence performed 6 h p.i.
demonstrates that HPV-L1 can also be detectable in
replication-permissive cells, although only at early times
of infection, when the vector is expressing non-struc-
tural enzymatic proteins with poor cytopathic effects.
Indeed, HPV-L1 expression was sometimes also found
in CEFs by immunoprecipitation, when the samples
were loaded in excess (our unpublished data). This sug-
gests early/low expression in these cells, which makes it
rarely detectable.
Similarly, HPV-L1 capsid proteins never appear to be
correctly structured as VLPs in CEFs, although they
were present in Vero and MRC-5 cells. While it is not
surprising that VLPs are not detectable in cells where
the recombinant replicates, as vector protein synthesis
might be detrimental to HPV-L1 production and VLP
assembly, the reason for the low VLP production in
Vero and MRC-5 cells is not completely clear. This can-
not be ascribed to the L1 gene coding sequence inserted
into FPL1, which, as with other constructs [31,49,50]
that can produce VLPs, starts from the second ATG.
Indeed, transcription from the first ATG prevents VLP
formation (M. Mueller, personal communication).
As already described [51], L1 capsid proteins can self-
assemble as single capsomers (pentamers), T1 particles
(12 pentamers) or complete VLPs (T7, 72 pentamers).
At the ultrastructural level, we demonstrated the pre-
s e n c eo fb o t hT 1a n dT 7p a r t icles. Although these are
present in limited amounts, this confirms that FP-driven
L1 proteins can, at least in part, self-assemble correctly.
Since the L1 protein produced by the FPL1 recombinant
has the NLS, nuclear localization is expected, in spite of
the vector transgene expression in the cytoplasm. T1
capsomers were found in the nucleus, which were still
not assembled as complete VLPs. VLPs were seen in
pseudo-vacuoles, although very rarely, as if they were in
the cytoplasm as a result of the tangential section of a
plasma membrane invagination. We suggest therefore
that the VLPs in the pseudo-vacuoles might represent
extracellular VLPs that were previously assembled in the
nucleus and were then released by already lysed cells.
We hypothesise that the GFP gene co-inserted with
the HPV-L1 transgene into the vector to track the
expression of the recombinant, the expression of which
is driven by the strong SP synthetic promoter, might
interfere with HPV-L1 expression. Although other stu-
dies have also used constructs containing GFP for
recombinant selection [31,52], the hypothesis that GFP
co-espression might hamper high production of the
heterologous gene and VLP assembly has already been
investigated by K. Kindsmueller (Institute of Medical
Microbiology and Hygene, University of Regensburg,
Germany, personal communication). By removing the
GFP gene, we also obtained higher gene expression
using other recombinants produced in our laboratory
(unpublished data).
The similar decrease over time in both HPV-L1 and
GFP mRNA transcripts shown by real-time PCR does
not correlate with the low amounts of VLP production.
However, data from our laboratory with recombinants
that co-express transgenes and GFP suggest that SP pro-
moter activity and/or GFP expression might interfere
negatively, by limiting the synthesis of the L1 protein
and VLP assembly. This might justify the good mRNA
expression for both of these transgenes up to 10 days p.
i. with very low VLP amounts.
It is therefore likely that HPV-L1 protein expression,
rather than mRNA, is responsible for the low VLP
assembly, which can justify the good mRNA expression
for both of these transgenes up to 10 days p.i. with very
low VLP amounts.
Therefore, before animal immunization, it will be
interesting to compare a new FPL1 construct lacking the
SP-GFP complex with the present FPL1 double recombi-
nant, both for the differences in mRNA and protein
expression and for VLP production.
Conclusions
As L1 appears to be correctly expressed both by replica-
tion restrictive and permissive cell lines, the FPL1
recombinant might represent a new prophylactic vac-
cine, which can putatively cross-present the antigen in
association with both MHC class I and II complexes.
This might contribute to a complete humoral and cellu-
lar immunity when compared to the commercially avail-
able vaccines. L1 expression was observed for almost
three weeks, and this is a pre-requisite for a durable
immune response. The limited amounts of assembled
VLPs seen by electron microscopy make these data pre-
liminary to the use of a modified construct for the ana-
lysis of the immune responses and protection in animal
models. Although the currently available vaccines are
efficient in eliciting a neutralizing immunity, the 7-year
efficacy appears limited since oncogenicity is often
revealed only after decades of incubation. An alive non-
replicating vaccine might fit the purpose better if it can
produce the L1 protein and VLPs.
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